Skip to main content
. Author manuscript; available in PMC: 2020 Nov 2.
Published in final edited form as: Genet Med. 2018 Feb 8;20(10):1274–1283. doi: 10.1038/gim.2017.262

Figure 3. Dramatically altered analytes in the peroxisome biogenesis disorders–Zellweger spectrum disorders (PBD-ZSD) metabolome.

Figure 3

(a) Box plots of analytes that are related to biochemical pathways known to be peroxisomal (see Supplementary Figure S1 online); error bars correspond to 95% confidence interval. (b) Box plots of alterations in sphingomyelins including palmitoyl sphingomyelin (palmitoyl sphingomyelin (d18:1/16:0)), palmitoleoyl sphingomyelin (sphingomyelin (d18:2/16:0, d18:1/16:1)*), oleoyl sphingomyelin (sphingomyelin (d18:1/18:1, d18:2/18:0)), nervonoyl sphingomyelin (sphingomyelin (d18:1/24:1, d18:2/24:0)*), myristoyl sphingomyelin (sphingomyelin (d18:1/14:0, d16:1/16:0)*), euricoyl sphingomyelin (sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)*), eicosenoyl sphingomyelin (sphingomyelin (d18:1/20:1, d18:2/20:0)*), and behenoyl sphingomyelin (behenoyl sphingomyelin (d18:1/22:0)*).